Dr. Pierre Kory on health: what the evidence says · JRE #1671

What the evidence says 01 / RECORD

The meta-analysis Kory referenced, by Bryant, Lawrie et al. (published in the American Journal of Therapeutics in mid-2021), reported roughly a 62% reduction in COVID-19 mortality among patients treated with ivermectin, pooling data from a number of randomized controlled trials. In January 2022 the same journal issued a formal Expression of Concern for that meta-analysis, noting that several of the included trials, most notably an Egyptian study by Elgazzar and colleagues that contributed heavily to the mortality signal, had serious data integrity problems and were later shown to contain likely fabricated or duplicated data; that trial was subsequently retracted from its preprint server. Once such compromised or low-quality trials are excluded, later and larger high-quality randomized trials found no significant mortality or clinical benefit from ivermectin: the NEJM-published TOGETHER trial (2022) and the JAMA-published ACTIV-6 trials (2022, 2023) each found ivermectin did not meaningfully reduce hospitalization, disease progression, or time to recovery compared with placebo. Current mainstream scientific consensus, reflected in these subsequent large trials, is that the 62% mortality-reduction figure Kory cited rested substantially on trials with serious methodological and integrity flaws and has not been replicated by more rigorous studies.